On February 9, 2021 Exelixis, Inc. (Nasdaq: EXEL) reported that it will host an investor briefing to discuss data presented at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)’s 2021 Genitourinary Cancers Symposium (ASCO GU 2021) (Press release, Exelixis, FEB 9, 2021, View Source [SID1234574791]). The online-only event will be held on Saturday, February 13, 2021, beginning at 5:30 p.m. EST / 2:30 p.m. PST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

During the briefing, Exelixis management and invited guests from the clinical community will discuss and provide context for cabozantinib clinical data presented at ASCO (Free ASCO Whitepaper) GU 2021, including updated results with extended follow-up data from CheckMate -9ER, the phase 3 pivotal trial evaluating CABOMETYX (cabozantinib) in combination with OPDIVO (nivolumab) compared with sunitinib as first-line treatment in patients with advanced or metastatic renal cell carcinoma (RCC). The investor briefing is also expected to include discussion of other ASCO (Free ASCO Whitepaper) GU 2021 data sets evaluating the use of cabozantinib in treatment settings for RCC and other genitourinary cancers.

To access the investor briefing, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the event to ensure adequate time for any software download that may be required to view the webcast. After the event concludes, a replay will be available at that same location for a minimum of one year.